AMGN Stock Outlook 2026: MariTide Phase 3 Is the Only Catalyst That Matters

Amgen heading into 2026 is a fundamentally bifurcated story. One half is the mature, cash-generating biopharmaceutical company — a steady dividend payer with a dominant biosimilar manufacturing operation, a broad inflammation and oncology franchise, and the newly acquired Horizon rare-disease portfolio. The other half is a high-stakes binary bet on MariTide, Amgen’s entry into the GLP-1 obesity market where Eli Lilly and Novo Nordisk have already built massive competitive advantages.

The investment recommendation from most institutional desks is some version of “wait for Phase 3 data.” That is not a cop-out — it is the analytically correct position when a single clinical readout can move a stock 15–25% in either direction, and when the base business is stable enough to hold while you wait.

Amgen’s Revenue Architecture in 2026

Three distinct revenue layers define Amgen’s profile:

Layer 1 — Eroding legacy products: Enbrel (etanercept) faces continued but slow erosion in the US; Prolia/XGEVA (denosumab) biosimilars are entering the market. These products still generate significant cash, but the trajectory is downward.

Layer 2 — Horizon acquisition assets: TEPEZZA and KRYSTEXXA are rare-disease premium-priced products with limited competition. Post-acquisition quarterly contributions are tracked in SEC EDGAR 10-Q filings under product-level revenue tables.

Layer 3 — Growth pipeline: MariTide (obesity), Olpasiran (cardiovascular), LUMAKRAS/sotorasib (oncology), and AMG 133 variants. Phase 3 timelines determine when, if ever, these contribute meaningful revenue.

Related: LLY Eli Lilly stock outlook 2026 →

GLP-1 Competitive Landscape: Where MariTide Fits

The GLP-1 market in 2026 is already dominated by two players. Eli Lilly’s tirzepatide (Zepbound for obesity, Mounjaro for diabetes) and Novo Nordisk’s semaglutide (Wegovy, Ozempic) have captured the market, built manufacturing scale, and established physician familiarity. Any new entrant needs a differentiated story.

Attribute	AMGN MariTide	LLY (tirzepatide)	NVO (semaglutide)
Mechanism	GIP/GLP-1 bispecific mAb	Dual GIP/GLP-1 agonist (peptide)	GLP-1 agonist (peptide)
Dosing	Monthly or less (target)	Weekly injection	Weekly injection
Phase	Phase 3 (ongoing)	Approved, market expansion	Approved, market expansion
Differentiation thesis	Lower dosing frequency	Best-in-class weight loss	Established brand + supply
US approval	Pending Phase 3 readout	Complete	Complete

Amgen’s differentiation claim rests on dosing frequency. A once-monthly or less-frequent injection would represent a meaningful patient experience improvement over weekly injections, which require consistent routine and create adherence challenges over years of treatment. Whether that difference is large enough to capture meaningful market share — especially given LLY and NVO’s pricing power and payer relationships — will only be answered by Phase 3 data and, eventually, real-world payer coverage decisions.

Biosimilar Erosion: The Numbers That Keep Shrinking

Amgen is simultaneously one of the world’s largest biosimilar developers (AMJEVITA, KANJINTI, MVASI) and a company whose legacy products face biosimilar competition. The irony is structurally significant.

Prolia/XGEVA (denosumab): Used for osteoporosis and cancer-related bone loss, these products represent a combined multi-billion-dollar annual revenue line. Biosimilar approvals accelerate in 2025–2026, and payer formulary pressure will push substitution. Track denosumab biosimilar launch timelines using FDA’s Purple Book (accessdata.fda.gov).

Enbrel (etanercept): The US market has been unusual — biosimilar launch has not translated to the rapid share loss seen in Europe, largely due to PBM contracts that make the originator preferentially positioned. This protection is gradually eroding as contracts come up for renewal.

The question for Amgen’s financial model: does Horizon + MariTide replace the eroding legacy revenue before FCF starts declining meaningfully? Check SEC EDGAR 10-K for year-over-year product revenue trend tables.

CMS Drug Price Negotiation: The IRA Risk

The Inflation Reduction Act gives CMS authority to negotiate prices for drugs that account for significant Medicare spend and are outside patent or exclusivity protection windows. Amgen’s product list is broad enough that multiple candidates could appear on future negotiation lists.

Structural factors that limit (but don’t eliminate) IRA exposure:

• Orphan drug exemptions protect rare-disease products below patient-count thresholds
• Biologics have a 13-year exclusivity period before negotiation eligibility (vs 9 years for small molecules)
• Horizon assets like TEPEZZA and KRYSTEXXA target small patient populations that may fall below negotiation thresholds

Track CMS.gov for the annually updated Medicare drug negotiation list. Amgen’s 10-K risk factor section specifically addresses IRA exposure for each major product.

How Amgen’s Patent Cliff Differs From Traditional Pharma

Traditional small-molecule drugs lose protection sharply at patent expiry, and generic entry immediately captures 80%+ of volume at steep price discounts within months. Biologic drugs like those Amgen makes behave differently. Biosimilar manufacturers face higher regulatory hurdles (demonstrating biosimilarity to FDA), higher manufacturing complexity, and — in the US specifically — a market structure where pharmacy benefit managers (PBMs) can negotiate formulary placement that slows generic-equivalent switching.

The result: Amgen’s biologics tend to see slower, more gradual market share erosion than small-molecule drugs at patent expiry. The denosumab (Prolia/XGEVA) erosion in 2025–2026 is the most relevant current example. Tracking market share data published in Amgen’s quarterly reports will show the actual penetration rate, which is almost always slower than pessimistic scenarios predict in the first 12–18 months, and then accelerates.

LUNSUMIO and the Oncology Pipeline Beyond MariTide

Amgen has a deep oncology pipeline extending beyond the headline obesity story. LUNSUMIO (mosunetuzumab, a CD20×CD3 bispecific antibody for follicular lymphoma) received full FDA approval and represents Amgen’s entry into the rapidly expanding bispecific antibody oncology space.

BiTE (Bispecific T-cell Engager) technology, pioneered by Amgen with Blincyto (blinatumomab), is now a validated drug class for hematologic malignancies. The next-generation BiTE candidates in Amgen’s pipeline could represent a durable oncology franchise separate from the obesity pipeline. For investors evaluating Amgen as more than a “MariTide binary trade,” the oncology pipeline depth is an important supporting argument for the base case.

Dividend Sustainability and Horizon Debt

Amgen’s dividend has grown consistently, and the company has maintained dividend payments even through acquisition-driven balance sheet stress. The $27.8 billion Horizon acquisition was funded primarily with debt, increasing Amgen’s leverage ratio meaningfully.

Key checks for dividend sustainability:

• FCF vs total debt service (interest + scheduled amortization)
• FCF payout ratio (dividends as % of FCF)
• Timeline for leverage ratio normalization

Amgen’s legacy business generates substantial FCF even during product erosion cycles, which provides a cushion. But in a scenario where biosimilar erosion accelerates and MariTide fails Phase 3, the FCF trajectory would bear watching for dividend safety.

For US investors, Amgen dividends are qualified and reported on Form 1099-DIV. In a taxable account, Amgen’s combination of moderate yield and capital appreciation creates a tax-efficient total return profile compared to high-yield bonds or REITs. In a Roth IRA, the tax-free compounding of both dividend and potential MariTide-driven appreciation makes a maximum-contribution year a logical time to add exposure before Phase 3 readout.

Bull and Bear Case

Bull case

• MariTide Phase 3 shows competitive weight-loss efficacy and monthly dosing is confirmed as a real differentiation
• TEPEZZA expands into new indications, growing Horizon revenue ahead of estimates
• Biosimilar penetration of denosumab is slower than feared due to payer formulary inertia
• Rate cuts improve the relative appeal of high-yield biopharma dividend stocks

Bear case

• MariTide Phase 3 data disappoints on efficacy versus tirzepatide or semaglutide
• Denosumab biosimilars capture faster-than-expected share, creating a revenue cliff
• CMS selects Amgen products for negotiation lists sooner than anticipated
• Acquisition debt limits capital allocation flexibility if FCF declines

Trigger to Watch

Phase 3 readout timing is the single most important external variable for Amgen in 2026–2027. Watch for FDA AdCom meetings and PDUFA date announcements for any accelerated MariTide approval pathway that might open up based on Phase 2 data extension. The Phase 3 trial design (primary endpoint: percent weight loss; key secondary: cardiovascular outcomes) is publicly registered on ClinicalTrials.gov — monitoring it for any protocol amendments or interim analysis announcements provides an early signal.

Olpasiran: The Cardiovascular Pipeline Bet

While MariTide gets most of the attention, Olpasiran is a genuinely differentiated cardiovascular asset that deserves mention. Olpasiran is a small interfering RNA (siRNA) therapeutic targeting Lp(a) — lipoprotein(a) — a genetically determined cardiovascular risk factor that statins do not address and that affects roughly 20% of the global population.

Lp(a) elevation is a meaningful risk factor for atherosclerotic cardiovascular disease, and no approved therapy specifically reduces it. Amgen’s Phase 3 OCEAN(a) trial is testing whether Olpasiran’s Lp(a) lowering translates into reduced cardiovascular events. If it does, the addressable population is enormous.

The investment implication: Olpasiran is a slow-burn optionality play that could become a major revenue contributor in the 2028–2030 timeframe if the outcomes trial succeeds. It doesn’t drive the 2026 thesis, but it represents a separate binary event that investors should monitor alongside MariTide.

Biosimilar Business: The Other Side of Amgen’s Position

Amgen is not just a victim of biosimilar competition — it is one of the world’s largest biosimilar developers. The biosimilar portfolio includes:

• AMJEVITA (adalimumab biosimilar, competing with AbbVie’s Humira): Now launched in the US, one of the largest biosimilar market opportunities ever
• KANJINTI (trastuzumab biosimilar): Competing with Herceptin in breast cancer treatment
• MVASI (bevacizumab biosimilar): Competing with Avastin in cancer treatment

The biosimilar business provides an offset to the erosion of legacy originator products. However, biosimilar markets tend to commoditize quickly, and the margins are structurally lower than originator product margins. The biosimilar portfolio is FCF-positive but not a premium-margin growth business.

This creates an interesting dynamic: Amgen competes against biosimilars made by other companies on its originator products while simultaneously competing with those same companies on biosimilar versions of their originator products.

R&D Intensity and Capital Allocation

Amgen’s R&D spend as a percentage of revenue is among the highest in large-cap biopharma. This reflects the dual investment required: maintaining the competitive science base for organic pipeline development while integrating the acquired Horizon assets.

For investors, the key question is whether R&D spending is being capitalized (adding to the balance sheet) or expensed immediately (hitting the income statement). Under GAAP, pharmaceutical companies generally expense R&D as it occurs rather than capitalizing it. This means Amgen’s reported earnings are reduced by the full R&D spend each year, which understates economic earnings during heavy investment cycles.

Non-GAAP EPS adjustments that add back some R&D-related items are common in biopharma earnings presentations. Understanding the GAAP vs non-GAAP difference — and what specific items are excluded — requires reading the reconciliation tables in SEC EDGAR earnings releases.

Positioning AMGN in a US Health Care Portfolio

Amgen is typically positioned alongside other large-cap biopharma names like AbbVie, Bristol Myers Squibb, and Regeneron to form a diversified large-cap biotech sleeve. Its characteristics relative to peers:

• Higher near-term pipeline risk than AbbVie (which has a more diversified approved product base) but greater upside from MariTide
• More defensive than pure-play clinical-stage biotechs, where a single Phase 3 failure can be catastrophic
• Less China/emerging market exposure than many global pharma companies, reducing geopolitical risk in the portfolio

For sector ETF exposure, Amgen is a significant holding in XBI (SPDR S&P Biotech ETF) and IBB (iShares Biotechnology ETF). It also appears in XLV (Healthcare Select SPDR) and VHT (Vanguard Health Care ETF), which blend pharma, biotech, and managed care for broader healthcare diversification.

For comparison on how GLP-1 competition is developing from the market-leader perspective, see our LLY 2026 outlook and MRK 2026 outlook.

---

This article is informational only and does not constitute investment advice. All clinical data references point to publicly available sources; verify current trial status at ClinicalTrials.gov and FDA.gov before drawing investment conclusions.